ArticleFrontiers in pharmacology2018
Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- The gut feeling in motion sickness.Communications biology · 2025Review
- A deep learning-based system for automatic detection of emesis with high accuracy in Suncus murinus.Communications biology · 2025Article
- Evaluating proxies for motion sickness in rodent.IBRO neuroscience reports · 2023Article
- Screening study of anti-emetics to improve GDF15-induced malaise and anorexia: Implications for emesis control.Physiology & behavior · 2023Article
- The Actions of Centrally Administered Nesfatin-1 on Emesis, Feeding, and Locomotor Activity inFrontiers in pharmacology · 2022Article
- Olanzapine Administration Reduces Chemotherapy-Induced Nausea Behavior in Rats.Biological research for nursing · 2021Article
- Review
- Role of PI3K/Akt/GSK-3 Pathway in Emesis and Potential New Antiemetics.Journal of cellular signaling · 2020Article
- The Benefits of Olanzapine in Palliating Symptoms.Current treatment options in oncology · 2020Review
- The brain-penetrating, orally bioavailable, ghrelin receptor agonist HM01 ameliorates motion-induced emesis in Suncus murinus (house musk shrew).British journal of pharmacology · 2020Article
- GDF15 Induces Anorexia through Nausea and Emesis.Cell metabolism · 2020Article
- Sulprostone-Induced Gastric Dysrhythmia in the Ferret: Conventional and Advanced Analytical Approaches.Frontiers in physiology · 2020Article
- Revisiting the physiology of nausea and vomiting-challenging the paradigm.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ghrelin has well-known activity to stimulate appetite and weight gain. Evidence suggests that ghrelin may also have effects in reducing chemotherapy-induced emesis via growth hormone secretagogue receptors (GHS-R1A) in the brain. However, it is not known whether the stimulation of GHS-R1A has broad inhibitory anti-emetic effects. In the present studies, we used Highlights: - The novel orally bioavailable brain-penetrating GHS-R1A agonist, HM01 (1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-Methyl-3,3-dimethyl-4-piperidyl]urea), antagonizes motion- and cisplatin-induced emesis.- HM01 did not reduce emesis induced by nicotine or by intragastric copper sulfate.- HM01 has positive effects on food consumption after treatment with nicotine.- HM01 has synergistic effects against cisplatin when combined with palonosetron and palonosetron/netupitant regimens.- It is suggested that GHS-R1A agonists may be protective against chemotherapy-induced nausea and vomiting in combination with traditional anti-emetics and against motion-induced emesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.